Katja Hatz1,2, Andreas Ebneter3, Cengiz Tuerksever1, Christian Pruente2,4, Martin Zinkernagel3. 1. Vista Klinik, Binningen, Switzerland. 2. Department of Ophthalmology, University of Basel, Basel, Switzerland. 3. Department of Ophthalmology, Inselspital, Bern, Switzerland. 4. Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland.
Abstract
PURPOSE: To investigate dexamethasone intravitreal implant 0.7 mg (DEX implant) for the treatment of diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy and evaluate predictive factors. METHODS: Two-centre retrospective interventional case series, including 40 eyes of 31 patients treated with DEX implant for at least 2 consecutive cycles. RESULTS: Mean ± SD intervals from implantation to recurrence in the first (4.2 ± 1.0 months) and second cycles (4.0 ± 0.9 months) were not significantly different. Best corrected visual acuity improved significantly (p < 0.001) by 7.0 ± 8.4 letters from baseline to month 2, and by 5.1 ± 6.9 letters between the first and second cycles. Central retinal thickness reduction 2 months after implantation was greater after the first (-194 ± 172 µm) than the second cycle (-134 ± 150 µm). Ellipsoid zone-external limiting membrane (EZ-ELM) disruption score decreased from 1.39 ± 1.16 at baseline to 1.24 ± 1.16 (p = 0.0832) after cycle 1 and remained stable 2 months after cycle 2. Eyes with persisting severe EZ-ELM disruption (score >2, n = 10) 2 months after the first DEX implant showed significantly (p = 0.0153) smaller visual acuity (VA) gains than eyes with less severe (score ≤2) EZ-ELM disruption. CONCLUSION: Repeated intravitreal DEX injections with average intervals of 4 months are valuable in patients with DME refractory to anti-VEGF therapy. Disorganization of outer retinal layers (EZ-ELM) may predict smaller VA gains if evaluated after initial reduction of macular oedema. The Author(s). Published by S. Karger AG, Basel.
PURPOSE: To investigate dexamethasone intravitreal implant 0.7 mg (DEX implant) for the treatment of diabetic macular oedema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy and evaluate predictive factors. METHODS: Two-centre retrospective interventional case series, including 40 eyes of 31 patients treated with DEX implant for at least 2 consecutive cycles. RESULTS: Mean ± SD intervals from implantation to recurrence in the first (4.2 ± 1.0 months) and second cycles (4.0 ± 0.9 months) were not significantly different. Best corrected visual acuity improved significantly (p < 0.001) by 7.0 ± 8.4 letters from baseline to month 2, and by 5.1 ± 6.9 letters between the first and second cycles. Central retinal thickness reduction 2 months after implantation was greater after the first (-194 ± 172 µm) than the second cycle (-134 ± 150 µm). Ellipsoid zone-external limiting membrane (EZ-ELM) disruption score decreased from 1.39 ± 1.16 at baseline to 1.24 ± 1.16 (p = 0.0832) after cycle 1 and remained stable 2 months after cycle 2. Eyes with persisting severe EZ-ELM disruption (score >2, n = 10) 2 months after the first DEX implant showed significantly (p = 0.0153) smaller visual acuity (VA) gains than eyes with less severe (score ≤2) EZ-ELM disruption. CONCLUSION: Repeated intravitreal DEX injections with average intervals of 4 months are valuable in patients with DME refractory to anti-VEGF therapy. Disorganization of outer retinal layers (EZ-ELM) may predict smaller VA gains if evaluated after initial reduction of macular oedema. The Author(s). Published by S. Karger AG, Basel.
Authors: Mark C Gillies; Lyndell L Lim; Anna Campain; Godfrey J Quin; Wedad Salem; Ji Li; Stephanie Goodwin; Christine Aroney; Ian L McAllister; Samantha Fraser-Bell Journal: Ophthalmology Date: 2014-08-22 Impact factor: 12.079
Authors: David S Boyer; David Faber; Sunil Gupta; Sunil S Patel; Homayoun Tabandeh; Xiao-Yan Li; Charlie C Liu; Jean Lou; Scott M Whitcup Journal: Retina Date: 2011-05 Impact factor: 4.256
Authors: Matteo Scaramuzzi; Giuseppe Querques; Carlo La Spina; Rosangela Lattanzio; Francesco Bandello Journal: Retina Date: 2015-06 Impact factor: 4.256
Authors: Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Ingrid Zimmer-Galler; Syed M Shah; Adam S Wenick; Christopher J Brady; Ian Han; Lingmin He; Roomasa Channa; David Poon; Catherine Meyerle; Mary Beth Aronow; Akrit Sodhi; James T Handa; Saleema Kherani; Yong Han; Raafay Sophie; Guohua Wang; Jiang Qian Journal: Am J Ophthalmol Date: 2016-04-27 Impact factor: 5.258
Authors: Helena Giannakaki-Zimmermann; Alexandra Behrndt; Laura Hoffmann; Maria-Magdalena Guichard; Cengiz Türksever; Christian Prünte; Katja Hatz Journal: Ophthalmic Res Date: 2021-01-26 Impact factor: 2.892
Authors: Patricia Udaondo; Alfredo Adan; Luis Arias-Barquet; Francisco J Ascaso; Francisco Cabrera-López; Verónica Castro-Navarro; Juan Donate-López; Alfredo García-Layana; Francisco Javier Lavid; Mariano Rodríguez-Maqueda; José María Ruiz-Moreno Journal: Clin Ophthalmol Date: 2021-07-27